Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy + Glofitamab in R/R DLBCL
NCT07634289Phase 2Not yet recruiting
- Sponsor
- Olivia Newton-John Cancer Research Institute
- Start
- Dec 2026
- Primary completion
- Dec 2031
- Countries
- 1
01
Overview
A Phase 2 trial of glofitamab in diffuse large B-cell lymphoma (DLBCL), sponsored by Olivia Newton-John Cancer Research Institute. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
glofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07634289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07634289.